EMA Emergency Task Force Recommends Bivalent COVID-19 Vaccines for Initial Inoculations
December 7, 2022
An Emergency Task Force (ETF) of the European Medicines Agency (EMA) has announced that it supports the use of bivalent mRNA COVID-19 vaccines for primary inoculations. The vaccines, which contain mRNA from the original SARS-CoV-2 and the Omicron BA.4/BA.5 strains, were previously only used as boosters for those who have already been vaccinated with one of the original versions of the shots.
According to the ETF, “Although there are limitations to the available data, it is reasonably expected that the bivalent original/Omicron BA4-5 mRNA vaccines can elicit priming against SARS-CoV-2 and that they would have a similar safety profile as the originally approved mRNA vaccines in previously unvaccinated persons”
To read more, click here.
(Source: PM Live, December 7th, 2022)
